Analysts anticipate Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.31. Anticipation surrounds Vertex Pharmaceuticals's announcement, with investors hoping to hear about both ...

MML Investors Services ramped up its Regeneron stake by 41.7%, acquiring 2,218 additional shares during Q4. This brings their ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

Regeneron Pharmaceuticals has received a total of 10 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $797.9, the consensus suggests a potential 32.4% ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Capital International Ltd. CA boosted its Regeneron Pharmaceuticals holdings by 14.5% in Q4, now holding nearly $29.2 million ...

US Stock Market Live | Dow Jones | Nasdaq Today | Global markets surged after Trump ruled out firing Fed Chair Powell and ...

Speaking on the Yes Bank's Q4 results 2025, Kotak Securities said, "We expect NIM at 2.3 per cent (10 bps decline QoQ), but there is likely to be a lot of volatility, given the nature of income ...

Regeneron Pharmaceuticals said it is working to determine a path forward for its treatment of several retinal conditions after the Food and Drug Administration said it didn't agree with the ...

Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...

Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “With this FDA decision, Dupixent is now approved for seven ...

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response ...